Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, today announced a €5 million EUR (c.$5.58 million USD) investment into its protein production and biophysical characterization capabilities and services from its parent company, FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies.